VCIM
OTLK icon

Velan Capital Investment Management’s Outlook Therapeutics OTLK Stock Holding History

Velan Capital Investment Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-247,084
Closed -$1.82M – 20
2024
Q2 		$1.82M Sell
247,084
-252,916
-51% -$2.03M 1.04% 12
2024
Q1 		$5.97M Buy
+500,000
New +$4.04M 2.71% 9

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Velan Capital Investment Management's OTLK Position: Q3 2024 in Review

Velan Capital Investment Management sold out of Outlook Therapeutics (OTLK) in Q3 2024, closing a stake of 247,084 shares — an estimated $1.82M sold.

Velan Capital Investment Management first reported a position in OTLK in Q1 2024 and held it in 2 quarters. The position peaked at $5.97M in Q1 2024. 66 funds tracked by Wall St. Rank hold OTLK as of Q3 2024.

  • Velan Capital Investment Management reported no remaining Outlook Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Velan Capital Investment Management sold 247,084 Outlook Therapeutics shares in Q3 2024, an estimated $1.82M.
  • Velan Capital Investment Management first reported a position in Outlook Therapeutics in Q1 2024 and held it in 2 quarters.
  • Velan Capital Investment Management's Outlook Therapeutics position peaked at $5.97M in Q1 2024.
  • 66 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2024.

Based on Velan Capital Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.